Equibles does not estimate personal net worth.
Get an email with a short summary when Fulgent Genetics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FLGT alertsBrandon Perthuis has spoken on 6 earnings calls across 1 company, most recently for Fulgent Genetics, Inc. on November 5, 2026. Fulgent Genetics, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Fulgent Genetics, Inc. includes Ming Hsieh (CEO), Paul Kim (CFO), Jian Xie (COO) and 6 others.
“We ended the quarter at $90.4 million, an increase of 8% year over year and 6% sequentially. We continued integration efforts for Baco and Strata DX during the third quarter, which contributed to the overall performance.”
“We ended the quarter at $85.4 million, an increase of 4% year-over-year and 20 percent sequentially. The second quarter, we did have the new acquisitions of BACO and Strata DX integrated, which contributed to the overall performance.”
“Q1 historically has been a little bit softer for us, and it is partially related to seasonality. Like this quarter, we did have, you know, our laboratories shut down multiple times due to weather.”
“We ended the fourth quarter at $83.3 million, which was an increase of 9% year-over-year and a slight decrease quarter-over-quarter. Looking at how we closed the year, total revenue came in at $322.7 million, which was an increase of approximately 14% year over year.”
“It was again another excellent quarter, delivering nearly $84 million in laboratory services revenue. Breaking down our results by business area, Precision Diagnostics was up $3.4 million or 7.3% sequentially and was up $7.2 million or 16.4% year-over-year.”
Source not stated
Diagnostics & Research · Healthcare
